Ascendia

  MARKET NEWS

Adare
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
Smithers Germany Medical Device Testing Lab Achieves ISO/IEC 17025 Accreditation
Evonik provides customers with Life Cycle Assessment data for selected EUDRAGIT polymers
Bespak Awarded Gold EcoVadis Sustainability Rating for its Holmes Chapel Site
Lonza Launches Rapid Custom Media Prototyping Service to Accelerate Early Bioprocess Development

  EXPERT CONTENT & RESOURCES

 

Improving bioavailability using predictive modeling for solubility enhancement

Improving bioavailability using predictive modeling for solubility enhancement

In this case study, predictive modeling with the OSDPredict™ platform was used to prioritize optimal formulation strategies for a program facing low-solubility challenges. This approach improved exposure and supported accelerated advancement toward Phase I clinical trials.

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production.

Vin Singh Bullfrog AI

BullFrog AI: Applying an End-to-end AI Workflow to Improve Clinical Development 

BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.

Nina Bauer

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

FDA QSMR Image

Navigating FDA QMSR in 2026 

For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

  COMPANY PROFILE

Company Logo

We care about making better therapeutics.

BIOVECTRA, now part of Agilent Technologies, is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, pDNA and mRNA manufacturing, cell banking, and fill/finish. Flexibility, creativity, process optimization, and compliance are at the heart of our method. Our teams leverage decades of expertise and a proven track record of excellence to optimize, adapt, and perfect innovative technologies and drug substance development approaches to deliver world-class solutions for pharmaceutical manufacturing.

Click here for more.

 

Company Logo

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers – from emerging biotechs to global pharmaceutical companies – to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Our vision is to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products

WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products

The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and …

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 2 – API Synthesis
September 9 – Bioavailability
September 16 – Capsules
September 23 – Analytical Testing

Company Profiles: